Brief: Merck's Keytruda Qlex Approved In Japan For Subcutaneous Administration For All Keytruda Indications Approved In Japan
21/09/2026 13:22
BRIEF-Merck's Keytruda Qlex Approved In Japan For Subcutaneous Administration For All Keytruda Indications Approved In Japan Sept 21 (Reuters) - Merck & Co Inc MRK.N:
MERCK’S KEYTRUDA QLEX™ (PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH) APPROVED IN JAPAN FOR SUBCUTANEOUS ADMINISTRATION FOR ALL KEYTRUDA® (PEMBROLIZUMAB) INDICATIONS APPROVED IN JAPAN
Source text: ID:nBw49rmXLa
Further company coverage: MRK.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Merck & Co
See all newsModerna sheds about $24 billion as cancer vaccine data triggers 'sell-the-news' retreat
Merck/Moderna cancer vaccine cuts melanoma death or recurrence risk by 42%, shares fall (updated)
Brief: Merck Says Intismeran Plus Keytruda Significantly Reduced Risk Of Recurrence Or Death By 42%
Merck/Moderna cancer vaccine cuts risk of death or recurrence from melanoma by over 40%
Moderna falls as social media posts flag potential cancer vaccine data leak